Analyzing Blood Samples for Glioma Diagnosis
Official title: Pilot Study of Liquid Biopsy as a Diagnostic Tool for Gliomas by Analyzing Circulating Tumor DNA in Blood Samples, and Its Validation With the Corresponding Tissue Biopsies.
Run by Corporacion Parc Tauli · NCT05964153 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new blood test to see if it can help diagnose gliomas in patients with brain lesions by looking for tumor DNA in their blood instead of using traditional tissue biopsies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Corporacion Parc Tauli Academic / other |
| Locations | 1 site (Sabadell, Barcelona) |
| Trial ID | NCT05964153 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a primary brain lesion compatible with glioma as seen on MRI.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or have a different diagnosis than glioma will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study investigates a new liquid biopsy approach for diagnosing gliomas by detecting circulating tumor DNA (ctDNA) in the blood of patients with brain lesions. The study utilizes minimally invasive blood sampling and employs digital PCR to enhance sensitivity in detecting ctDNA. The results from blood samples will be compared to tissue biopsies to assess the reliability of this method. The goal is to standardize a protocol for glioma diagnosis that could be beneficial for patients with challenging tumor locations.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive and more accurate method for diagnosing gliomas.
How similar studies have gone: Other studies have shown promise in using liquid biopsy techniques for cancer diagnosis, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * De novo primary brain lesion, compatible with a glioma according to contrast-enhanced magnetic resonance images. The injury must be treated by the usual surgical procedure. * Signature of informed consent. Exclusion Criteria: * Pregnant or breastfeeding women. * Reasonable doubts in the diagnosis of glioma by magnetic resonance, or patients whose tissue biopsy diagnoses a brain lesion other than a glioma. * Patients who cannot undergo surgical resection, or when the tissue samples taken are not significant enough to be analyzed. * Inability or disagreement with signing the informed consent.
Where it's running
-
Hospital Universitari Parc Taulí
Sabadell, Barcelona, Spain Recruiting
Study contacts
- Principal investigator: Silvia Gil — Hospital Universitari Parc Taulí
- Study coordinator: Coloma Moreno
- Email: cmoreno@tauli.cat
- Phone: +34937231010
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
YN003 injection in glioma patients
This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.
-
Brain connectome project in adults with brain glioma undergoing surgery
This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.
-
Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas
This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.
-
Connectome-guided network planning for brain tumor surgery in eloquent areas
This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.
-
AI-powered analysis of brain MRI to help glioma care
Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.
-
Safusidenib in IDH1-mutant glioma after vorasidenib progression
This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.